Erratum: Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant acinetobacter baumannii infection (American Society for Microbiology (2017) 61:10 (e00954-17) DOI: 10.1128/AAC.00954-17);Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 10, 2017, Pages

  Schooley, Robert T ^a   Biswas, Biswajit ^b,c   Gill, Jason J ^d,e   Hernandez Morales, Adriana ^d   Lancaster, Jacob ^e   Lessor, Lauren ^e   Barr, Jeremy J ^f,m   Reed, Sharon L ^a,g   Rohwer, Forest ^f   Benler, Sean ^f   Segall, Anca M ^f   Taplitz, Randy ^a   Smith, Davey M ^a   Kerr, Kim ^a   Kumaraswamy, Monika ^a   Nizet, Victor ^h,i   Lin, Leo ^h   McCauley, Melanie D ^a   Strathdee, Steffanie A ^a   Benson, Constance A ^a   Pope, Robert K ^j   Leroux, Brian M ^j   Picel, Andrew C ^k   Mateczun, Alfred J ^b   Cilwa, Katherine E ^b   Regeimbal, James M ^b   Estrella, Luis A ^b   Wolfe, David M ^b   Henry, Matthew S ^b,c   Quinones, Javier ^b,c   Salka, Scott ^l   Bishop Lilly, Kimberly A ^b,c   Young, Ry ^d,e   Hamilton, Theron ^b   more..

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b NAVAL MEDICAL RESEARCH CENTER   (United States)

^c HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^d TEXAS A AND M UNIVERSITY   (United States)

^e TEXAS A AND M UNIVERSITY   (United States)

^f SAN DIEGO STATE UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁱ UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^j National Biodefense Analysis and Countermeasures Center   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l AmpliPhi Biosciences Corporation   (United States)

^m MONASH UNIVERSITY   (Australia)

more..

Author keywords

Acinetobacter; Bacteriophage therapy; Multidrug resistance

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; FLUCONAZOLE; GENTAMICIN; MEROPENEM; MINOCYCLINE; RIFAMPICIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ABSCESS; ACINETOBACTER INFECTION; ACUTE HEMORRHAGIC PANCREATITIS; AGED; ARTICLE; BACTERIOPHAGE; BACTERIUM ISOLATE; CASE REPORT; CLINICAL ARTICLE; DIABETIC PATIENT; HEALTH; HUMAN; LABORATORY; MALE; PANCREAS PSEUDOCYST; PERCUTANEOUS DRAINAGE; PHAGE THERAPY; PRIORITY JOURNAL; ACINETOBACTER BAUMANNII; CLASSIFICATION; DRUG EFFECT; GALLSTONE; ISOLATION AND PURIFICATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; PATHOLOGY; PROCEDURES; VIROLOGY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AGED; ANTI-BACTERIAL AGENTS; BACTERIOPHAGES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GALLSTONES; HUMANS; MALE; MINOCYCLINE; PANCREATIC PSEUDOCYST; PANCREATITIS, ACUTE NECROTIZING; PHAGE THERAPY;

EID: 85029766008     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02221-18     Document Type: Erratum

References (31)

1. Anonymous. 2013. Antibiotic resistance threats in the United States. Centers for Disease Control and Prevention, Atlanta, GA.
2. Ventola CL. 2015. The antibiotic resistance crisis: part 1: causes and threats. P T 40:277–283.
3. Calhoun JH, Murray CK, Manring MM. 2008. Multidrug-resistant organisms in military wounds from Iraq and Afghanistan. Clin Orthop Relat Res 466:1356 –1362. https://doi.org/10.1007/s11999-008-0212-9.
4. Arias CA, Murray BE. 2009. Antibiotic-resistant bugs in the 21st century - a clinical super-challenge. N Engl J Med 360:439–443. https://doi.org/10.1056/NEJMp0804651.
5. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21:538–582. https://doi.org/10.1128/CMR.00058-07.
6. Pendleton JN, Gorman SP, Gilmore BF. 2013. Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther 11:297–308. https://doi.org/10.1586/eri.13.12.
7. Brown ED, Wright GD. 2016. Antibacterial drug discovery in the resistance era. Nature 529:336–343. https://doi.org/10.1038/nature17042.
8. Spellberg B, Bartlett JG, Gilbert DN. 2013. The future of antibiotics and resistance. N Engl J Med 368:299–302. https://doi.org/10.1056/NEJMp1215093.
9. Regeimbal JM, Jacobs AC, Corey BW, Henry MS, Thompson MG, Pavlicek RL, Quinones J, Hannah RM, Ghebremedhin M, Crane NJ, Zurawski DV, Teneza-Mora NC, Biswas B, Hall ER. 2016. Personalized therapeutic cocktail of wild environmental phages rescues mice from Acinetobacter baumannii wound infections. Antimicrob Agents Chemother 60:5806–5816. https://doi.org/10.1128/AAC.02877-15.
10. Biswas B, Adhya S, Washart P, Paul B, Trostel AN, Powell B, Carlton R, Merril CR. 2002. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Im-mun 70:204–210. https://doi.org/10.1128/IAI.70.1.204-210.2002.
11. Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, Adhya S. 1996. Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci U S A 93:3188–3192. https://doi.org/10.1073/pnas.93.8.3188.
12. Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A. 2009. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care 18:237–238, 240–233. https://doi.org/10.12968/jowc.2009.18.6.42801.
13. Smith HW, Huggins MB. 1983. Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J Gen Microbiol 129:2659–2675.
14. Smith HW, Huggins MB. 1982. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol 128:307–318.
15. Wright A, Hawkins CH, Anggard EE, Harper DR. 2009. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 34:349 –357. https://doi.org/10.1111/j.1749-4486.2009.01973.x.
16. Sarker SA, Berger B, Deng Y, Kieser S, Foata F, Moine D, Descombes P, Sultana S, Huq S, Bardhan PK, Vuillet V, Praplan F, Brussow H. 2017. Oral application of Escherichia coli bacteriophage: safety tests in healthy and diarrheal children from Bangladesh. Environ Microbiol 19:237–250. https://doi.org/10.1111/1462-2920.13574.
17. Sarker SA, Sultana S, Reuteler G, Moine D, Descombes P, Charton F, Bourdin G, McCallin S, Ngom-Bru C, Neville T, Akter M, Huq S, Qadri F, Talukdar K, Kassam M, Delley M, Loiseau C, Deng Y, El Aidy S, Berger B, Brussow H. 2016. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. EBioMedicine 4:124–137. https://doi.org/10.1016/j.ebiom.2015.12.023.
18. Oechslin F, Piccardi P, Mancini S, Gabard J, Moreillon P, Entenza JM, Resch G, Que YA. 2017. Synergistic interaction between phage therapy and antibiotics clears Pseudomonas aeruginosa infection in endocarditis and reduces virulence. J Infect Dis 215:703–712. https://doi.org/10.1093/infdis/jiw632.
19. Henry M, Biswas B, Vincent L, Mokashi V, Schuch R, Bishop-Lilly KA, Sozhamannan S. 2012. Development of a high throughput assay for indirectly measuring phage growth using the OmniLog(TM) system. Bacteriophage 2:159–167. https://doi.org/10.4161/bact.21440.
20. Estrella LA, Quinones J, Henry M, Hannah RM, Pope RK, Hamilton T, Teneza-Mora N, Hall E, Biswajit B. 2016. Characterization of novel Staphylococcus aureus lytic phage and defining their combinatorial virulence using the OmniLog(R) system. Bacteriophage 6:e1219440. https://doi.org/10.1080/21597081.2016.1219440.
21. De Gelder J, De Gussem K, Vandenabeele P, Moens L. 2007. Reference database of Raman spectra of biological molecules. J Raman Spectrosc 38:1133–1147. https://doi.org/10.1002/jrs.1734.
22. Socrates G. 2004. Infrared and Raman characteristic group frequencies, 3rd ed. John Wiley & Sons Ltd, New York, NY.
23. Stratton CW. 2017. Phages, fitness, virulence, and synergy: a novel approach for the therapy of infections caused by Pseudomonas aeruginosa. J Infect Dis 215:668–670.
24. Knezevic P, Curcin S, Aleksic V, Petrusic M, Vlaski L. 2013. Phage-antibiotic synergism: a possible approach to combatting Pseudomonas aeruginosa. Res Microbiol 164:55–60. https://doi.org/10.1016/j.resmic.2012.08.008.
25. Nouraldin AAM, Baddour MM, Harfoush RAH, Essa SAM. 2016. Bacteriophage-antibiotic synergism to control planktonic and biofilm producing clinical isolates of Pseudomonas aeruginosa. Alexandria Med J 52: 99–105. https://doi.org/10.1016/j.ajme.2015.05.002.
26. Geisinger E, Isberg RR. 2015. Antibiotic modulation of capsular exopo-lysaccharide and virulence in Acinetobacter baumannii. PLoS Pathog 11:e1004691. https://doi.org/10.1371/journal.ppat.1004691.
27. Dufour N, Delattre R, Ricard JD, Debarbieux L. 2017. The lysis of pathogenic Escherichia coli by bacteriophages releases less endotoxin than by beta-lactams. Clin Infect Dis 64:1582–1588. https://doi.org/10.1093/cid/cix184.
28. Cisek AA, Dabrowska I, Gregorczyk KP, Wyzewski Z. 2017. Phage therapy in bacterial infections treatment: one hundred years after the discovery of bacteriophages. Curr Microbiol 74:277–283. https://doi.org/10.1007/s00284-016-1166-x.
29. Alonso AN, Perry KJ, Regeimbal JM, Regan PM, Higgins DE. 2014. Identification of Listeria monocytogenes determinants required for biofilm formation. PLoS One 9:e113696. https://doi.org/10.1371/journal.pone.0113696.
30. Bonilla N, Rojas MI, Netto Flores Cruz G, Hung SH, Rohwer F, Barr JJ. 2016. Phage on tap-a quick and efficient protocol for the preparation of bacteriophage laboratory stocks. PeerJ 4:e2261. https://doi.org/10.7717/peerj.2261.
31. Adams MH. 1959. Bacteriophages, 2nd ed. Interscience Publishers Inc, New York, NY.